Life-threatening SARS-CoV-2 Infection in Children: A Single-center Case Series

Sedigheh Rafiei Tabatabaei, Abdollah Karimi, Shahnaz Armin, Seyed Alireza Fahimzad, Roxana Mansour Ghanai, Saeed Sadr, Mitra Khalili, Amirhossein Hosseini, Hojjat Derakhshanfar, Mina Alibeik and Mehrdad Yasaei

1Pediatric Infectious Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Pediatric Pulmonology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Pediatric Radiology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Department of Pediatric Gastroenterology, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5Department of Pediatric Emergency, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

1Corresponding author: Pediatric Infectious Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: mehrdad.yasaei@gmail.com

Received 2020 July 19; Revised 2020 December 05; Accepted 2020 December 06.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is known as the most recent pandemic condition declared by the World Health Organization (WHO). It is widely believed that this infection is less frequent and severe in children, but few mortality reports are available in this age group population.

Case Presentation: We described nine pediatric patients with probable or confirmed COVID-19 who died due to disease complications. Their age ranged between seven months and 14 years. All had underlying diseases, and three of them had been hospitalized before the COVID-19 diagnosis due to their previous medical conditions. Cough and respiratory symptoms were the most common symptoms observed in these patients. Bilateral ground-glass opacities were common radiologic findings.

Conclusions: Although COVID-19 is less common in the pediatric group, all ages are vulnerable to this infection, and mortality may occur, especially in patients with underlying diseases. We emphasize that children with underlying diseases and COVID-19 should be hospitalized and monitored tightly during treatment.

Keywords: COVID-19, SARS-CoV-2, Mortality, Children

1. Introduction

Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, the capital of Hubei province, China, with the presentation of severe fatal respiratory illness in December 2019. Studies showed that the pathogenic agent is a novel coronavirus, named severe acute respiratory syndrome coronavirus-2 (SARS CoV-2). Soon, with dramatic worldwide spread, the World Health Organization (WHO) declared this condition a pandemic health emergency. To date, with more than 1.5 million affected people worldwide, a variety of respiratory and non-respiratory symptoms of this infection have been reported (1).

Fortunately, COVID-19 is less frequent and has a milder clinical course in children. However, the infection has been reported in all age groups even in the neonatal period. A few reports and guidelines have been published to date, demonstrating the epidemiologic and management protocols in children with COVID-19, of which almost none described the mortality rate among this group (2, 3).

In this article, we describe a series of nine pediatric patients admitted to our hospital with a diagnosis of COVID-19 as the cause of death. Although only two patients were tested positive for SARS-CoV-2 PCR and considered as definite cases, based on the importance of COVID-19 mortality, especially in children, the other patients were defined and presented as probable cases.

2. Case Presentation

A total of 130 pediatric patients were admitted to Mofid children's hospital from February to May 2020 suspected of or diagnosed with COVID-19 infection. Here, nine patients are reported with confirmed or suspected COVID-19 infection who died due to the complications of this disease. Patients’ clinical and paraclinical presentations are summarized in Table 1. Also, medical management and
Paraclinical findings are categorized in Table 2. Based on the national guideline for diagnosis and management of COVID-19, suspected cases are defined as patients with the presentation of dry cough, chills, or sore throat accompanied by dyspnea with or without fever. The probable cases are suspected patients with typical imaging findings in chest CT scans (ground-glass opacities, bilateral or unilateral peripheral chest infiltrations). Patients with positive PCR for SARS-CoV-2 were considered as confirmed cases (4). The chest CT scan cuts of five patients will be shown in Figures 1 to 5 later in the text. Despite the radiologic reports, other chest CT scan cuts were not available at the time of writing this article.

2.1. Cases 1, 2, and 3

Case 1 was a 14-month-old girl with Krabbe syndrome and a history of seizure and recurrent pneumonia. She was referred to our hospital with severe respiratory distress and cyanosis who had been intubated at a previous medical center due to cardiopulmonary arrest. She had a history of cough and increased respiratory rate a month before admission. Based on chest CT scan findings, she was diagnosed with COVID-19. Despite immediate initiation of both anti-viral and antibiotic therapies, she passed away with the clinical picture of ARDS and cardiogenic shock five days after admission.

Case 2 was a two-year-old girl, a known case of mucopolysaccharidosis, visiting our emergency ward with respiratory distress and knee swelling. The symptoms had emerged five days before visiting the hospital. Chest CT scan revealed multifocal, diffuse ground-glass opacities and consolidations in both lungs; thus, she was admitted to the COVID-19 ward. Even after hydroxychloroquine and intravenous antibiotic initiation, oxygenation worsened during her clinical course, necessitating invasive mechanical ventilation (IMV). She finally expired with cardiac arrest and shock one week after admission.

Patient 3 was a nine-year-old boy with cerebral palsy and controlled seizures. He was first presented with loss of consciousness and respiratory distress that occurred on the day of referral. Cardiopulmonary resuscitation was performed before being referred to our hospital. At the time of admission, he was on mechanical ventilation. Parents stated a history of cough and myalgia in family members 10 days ago. Chest CT scan findings were compatible with the COVID-19 pattern. Soon after diagnosis, wide-spectrum antibiotics and hydroxychloroquine were initiated. Ultimately, six days later, the patient passed away secondary to cardiac arrest.
2.2. Cases 4, 5, and 6
Cases 4, 5, and 6 were all hospitalized in our center because of their underlying diseases. Case 4 was a 13-year-old boy with hepatic failure and a history of close contact with a suspicious person two weeks before symptoms onset. Case 5 was a 14-year-old girl with extensive shotgun wounds, and Case 6 was a seven-month-old girl admitted with a complicated ventricular septal defect (VSD). Case 5 was admitted and hospitalized in our center for eight months. They had all experienced cough. The first two cases also had gastrointestinal symptoms, and the PCR tested positive for COVID-19. Except for patient 6 with congenital heart disease, echocardiography showed no abnormality. Case 4 died with the picture of LOC and encephalopathy one month after diagnosis. Cases 5 and 6 passed away two weeks after symptoms initiation, and the results of DIC and cardiac arrhythmia with wide QRS complex and bradycardia led to asystole, respectively.

Figure 1. Chest CT scan of Case No. 2 showing multifocal diffused ground-glass and linear opacities in both lungs; collapsed consolidation and air-bronchogram are visible.

Figure 2. Chest CT scan of Case No. 3 showing bilateral, mixed, multifocal, and peripheral ground-glass opacities and consolidations. Linear opacity is also seen.

Figure 3. Mixed multifocal and peripheral ground-glass opacities and round/linear consolidations in Chest CT scan of Case No. 4

Figure 4. Diffused, ground-glass opacities, and consolidation, besides bilateral pleural effusion and pericardial effusion in Case No. 5 with positive SARS-CoV-2 PCR
2.3. Cases 7, 8, and 9

Case 7 was a 17-month-old boy with complaints of fever, non-purulent conjunctivitis, nausea, and vomiting four days before admission. Chest CT scan showed peripheral ground-glass opacities in the upper and lower lobes of both lungs. Also, he fulfilled atypical Kawasaki disease criteria and underwent IVIG transfusion. Fever disappeared after IVIG administration. Echocardiography revealed coronary artery involvement. He was discharged from the hospital after recovery one week later. However, two days after discharge, he was expired with the presentation of respiratory distress, cyanosis, and cardiac arrest at home despite resuscitation operations delivered by emergency service.

Two other patients presented with respiratory distress and cough. Case 8 suffered from aplastic anemia, and the last patient was a five-year-old girl with severe neurodevelopmental delay and swallowing problems, living in a nursing center. The caregiver of the last patients stated a history of upper respiratory infection symptoms in some other children in their centers. Case 8 died one week after hospitalization with the presentation of respiratory distress and cardiac arrest. Eleven days after the beginning of the symptoms and four days after hospitalization, despite antiviral initiation from the first day, Case 9 passed away with respiratory failure and irreversible shock.

3. Discussion

By November 8, the COVID-19 pandemic caused > 49,000,000 infections and > 1,000,000 deaths globally. Children in all age groups seem to be susceptible to this infection although mortality rates were less than 1% in previous reports (5-7).

In this article, we presented nine children with probable or confirmed COVID-19 infection, admitted to our pediatric tertiary center. Their age ranged between seven months and 14 years. All had underlying diseases and three of them were hospitalized at the time of diagnosis due to their previous conditions. Only two of these patients had positive RT-PCR for COVID-19 from nasopharyngeal sampling. However, due to some limitations, we only had one PCR sample for each patient, for whom radiologic findings could not be explained with conditions other than COVID-19. This finding is compatible with a previous report in our country and could be explained by sampling errors or inadequate test sensitivity (8). Cough (55.5%) and fever (33%) were the most common findings in their history. Chest CT scans of our patients showed mostly ground-glass opacities with both mixed or separated consolidations. Both lungs were involved in all cases. Halo sign and reversed halo sign were seen in the patient with positive RT-PCR for SARS-CoV-19. Lymphopenia was observed in 45.5% of the patients. Also, Thrombocytopenia and elevated CRP were detected in 33.3% and 77.7% of the cases, respectively. Most of the cases (66%) eventually warranted invasive mechanical ventilation for breathing support and oxygenation.

Case 7, a 17-month-old male with atypical Kawasaki disease presentations, died with symptoms of cardiac involvement. In this case, echocardiography during hospitalization showed no abnormalities, and he became symptom-free after IVIG infusion. He was being managed with hydroxychloroquine for COVID-19. It seems that late-onset cardiac involvement of COVID-19 or arrhythmogenic effects of hydroxychloroquine in this vulnerable patient may have been the cause of death.

Patient No. 2 was a two-year-old child with MPS. Patients with this lysosomal storage disease are more susceptible to chronic lung infections due to their chest deformity and subsequent defective ventilation. This condition would lead to more serious SARS-CoV-2 infection and less compliance to COVID-19 complications. Also, due to the deformities of the oropharyngeal and laryngeal area, ventilation supportive care was more difficult and demanded critical consideration.

Most pediatric cases with COVID-19 to date have been reported from China, the United States, and Italy. Fortunately, these groups account for less proportion of infected population and mortality. Fever, cough, malaise, and gastrointestinal manifestations were the main clinical features of COVID-19 in children. In the report of the
Table 2. Paraclinical Findings and Medications of Nine Pediatric Cases With COVID-19 Infection

| Case No. | WBC (µL) | Lymphocyte (%) | ESR (mm/h) | CRP (mg/dL) | AST (IU/L) | ALT (IU/L) | Ph. PO2 (mmHg) | PCo2 (mmHg) | HCO3 (mEq/L) | SARS-CoV-2 RT-PCR | Chest CT Findings | Medications |
|----------|----------|----------------|------------|-------------|------------|------------|----------------|-------------|--------------|------------------|------------------|-------------|
| 1        | 13.6     | 16             | 2.1        | 236         | 35         | 2+         | 66             | 24          | 7.25         | Negative         | Multifocal, peripheral GGO/linear opacities in RUL, RLL, LLL | Chloroquine, Oseltamivir, Azithromycin, Meropenem, Ribavirin |
| 2        | 7.4      | 32             | 2.3        | 200         | 5          | 1+         | 48             | 40          | 7.14         | Negative         | Mixed multifocal peripheral GGO/consolidation and linear opacity in LUL, LLL | Chloroquine, Meropenem, Vancomycin |
| 3        | 10       | 9.4            | 0.94       | 262         | 60         | 4+         | 26             | 63          | 7.29         | Positive         | Diffused, GGO/Consolidation in RLL, LLL, RUL | Chloroquine, Ceftriaxone, Vancomycin |
| 4        | 3.4      | 19             | 7.3        | 298         | 109        | 20.1       | 56             | 11          | 9.3          | Negative         | Negative          | Chloroquine, Oseltamivir, Amikacin, Linezolid, Piperacillin/Tazobactam |
| 5        | 16.2     | 21             | 2.3        | 234         | 7.42       | Negative   | 7.42           | 392         | 6            | Negative         | Diffused, GGO/Consolidation in RUL, Multifocal, diffuse GGO/linear opacities in LUL, LLL | Chloroquine, Oseltamivir, Cefotaxim |
| 6        | 16.2     | 21             | 2.3        | 234         | 7.42       | Negative   | 7.42           | 392         | 6            | Negative         | Diffused, GGO/Consolidation in RUL, Multifocal, diffuse GGO/linear opacities in LUL, LLL | Chloroquine, Oseltamivir, Cefotaxim |
| 7        | 16.2     | 21             | 2.3        | 234         | 7.42       | Negative   | 7.42           | 392         | 6            | Negative         | Diffused, GGO/Consolidation in RUL, Multifocal, diffuse GGO/linear opacities in LUL, LLL | Chloroquine, Oseltamir, Cefotaxim |
| 8        | 16.2     | 21             | 2.3        | 234         | 7.42       | Negative   | 7.42           | 392         | 6            | Negative         | Diffused, GGO/Consolidation in RUL, Multifocal, diffuse GGO/linear opacities in LUL, LLL | Chloroquine, Oseltamir, Cefotaxim |
| 9        | 16.2     | 21             | 2.3        | 234         | 7.42       | Negative   | 7.42           | 392         | 6            | Negative         | Diffused, GGO/Consolidation in RUL, Multifocal, diffuse GGO/linear opacities in LUL, LLL | Chloroquine, Oseltamir, Cefotaxim |

Abbreviations: WBC, White Blood Cells; ALC, Absolute Lymphocyte Count; ESR, Erythrocyte Sedimentation Rate; CRP, C-Reactive Protein; AST, Aspartate Aminotransferase; ALT, Alanine Transaminase; RUL, Right Upper Lobe; RML, Right Middle Lobe; RLL, Right Lower Lobe; LUL, Left Upper Lobe; LLL, Left Lower Lobe; GGO, Ground-Glass Opacity.

Footnotes

Authors’ Contribution: Study concept and design, SR. Tabatabaei and A. Karimi; Acquisition of data, M. Alibeik and M. Yasaei; Analysis and interpretation of data, A. Fahimzad, S. Armin, A. Karimi, and R. Ghanaie; Drafting of the manuscript, M. Yasaei; Critical revision of the manuscript for important intellectual content, SR. Tabatabaei and A. Karimi; Administrative, technical, and material support, A. Hosseini, H. Derakhshanfar, S. Sadr, and M. Khalili; Study supervision, A. Karimi and SR. Tabatabaei.

Conflict of Interests: The authors declare no conflicts of interest.

United States, one-third of the pediatric cases were aged 15 - 17 years. Also, in this study, children less than one-year-old age had the highest rate of hospitalization. Imaging findings have not been described specifically in children, although bilateral or unilateral involvement, including ground-glass opacities or patchy infiltrations were previously reported in some articles. Studies in China, the United States, and Italy showed that the mortality rate increases with age substantially. Due to fewer reported cases in patients under the age of 20, the exact etiology for these findings needs to be clarified (9-19).

The low rate of positive SARS CoV-2 RT-PCR in this report may be explained by the low sensitivity of this test. Due to false-negative results of RT-PCR in the diagnosis of COVID-19, several studies suggested chest CT scan for the early detection of the disease. It seems that typical clinical presentations with characteristic imaging findings could confirm the diagnosis despite a negative RT-PCR test (16-19).

This study has some limitations, as mentioned before. The lack of test availability and accuracy at the time of diagnosis is the most important limitation of this study. Also, other confirmation tests such as antibody level measurement were not available at that time. Today, with better diagnostic facilities, more confirmed patients will be detected.

At last, it should be considered that although the mortality rate of COVID-19 is lower in children, it could lead to serious conditions in patients with underlying diseases. Also, hospital staff or caregivers could be potential infection carriers for hospitalized patients in medical centers. In conclusion, we recommend that children and adolescents with underlying diseases who are suspected or confirmed cases of COVID-19 should be hospitalized and vigorously treated. Also, since medical management is not specific yet, tight monitoring of vital signs and multi-organ functions must be considered according to their underlying conditions during the treatment process.
Ethical Approval: The article was approved by the Ethics Committee of Mofid Children’s Hospital.

Funding/Support: The article was supported financially by any institute or person.

Informed Consent: It was not declared by the authors.

References

1. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-24. doi: 10.4014/jmb.2003.0301N. [PubMed: 32238757].

2. Shen KL, Yang YH, Jiang RM, Wang YJ, Zhao DC, Jiang Y, et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition). World J Pediatr. 2020;16(3):213-9. doi: 10.1007/s12519-020-00362-4. [PubMed: 32131248]. [PubMed Central: PMC7806551].

3. De Rose DU, Piersigilli F, Ronchetti MP, Santisi A, Bersani I, Dotta A, et al. Novel Coronavirus disease (COVID-19) in newborns and infants: what we know so far. Ital J Pediatr. 2020;46(1):56. doi: 10.1186/s11604-020-00820-x. [PubMed: 32449772]. [PubMed Central: PMC790209].

4. Ministry of Health and Medical Education. Flow chart for diagnosis and management of COVID-19 in medical centers. 2020. Available from: http://corona.behdasht.gov.ir/page/66/.

5. WHO. Weekly epidemiological update - 10 November 2020. 2020. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update---10-november-2020.

6. Lu X, Zhang L, Du H, Zhang J, Li YY, Qi J, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382(17):1663-5. doi: 10.1056/NEJM2005073. [PubMed: 32187458]. [PubMed Central: PMC7212177].

7. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6). doi: 10.1542/peds.2020-0702. [PubMed: 32179660].

8. Rahimzadeh S, Eksiri-Noghabi M, Kadkhodaei Efkedariani F, Navaeifar MR, Enayati AA, Manafi Anari A, et al. COVID-19 infection in Iranian children: A case series of 9 patients. J Pediatr Rev. 2020;33(9):44. doi: 10.3259/jpr2.8.2139.

9. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: A systematic review. JAMA Pediatr. 2020;174(9):882-9. doi: 10.1001/jamapediatrics.2020.1467. [PubMed: 3220004].

10. Cdc Covid-19 Response Team. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422-6. doi: 10.15585/mmwr.mm691444. [PubMed: 3227728]. [PubMed Central: PMC747901].

11. Parri N, Lenge M, Buonsenso D; Coronavirus Infection in Pediatric Emergency Departments Research Group. Children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020;383(2):189-90. doi: 10.1056/NEJMc2007667. [PubMed: 32356945]. [PubMed Central: PMC7205693].

12. Li W, Cui H, Li K, Fang Y, Li S. Chest computed tomography in children with COVID-19 respiratory infection. Pediatr Radiol. 2020;50(6):796. doi: 10.1007/s00247-020-04656-7. [PubMed: 32162081]. [PubMed Central: PMC7080075].

13. Arentz M, Yim E, Klaft L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612-4. doi: 10.1001/jama.2020.4326. [PubMed: 32991259]. [PubMed Central: PMC7082763].

14. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574-81. doi: 10.1001/jama.2020.5394. [PubMed: 32250385]. [PubMed Central: PMC7196855].

15. Richardson S, Hirsch JS, Narasimhan M, Crawford JR, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. doi: 10.1001/jama.2020.5775. [PubMed: 32320001]. [PubMed Central: PMC771629].

16. West CP, Montori VM, Sampathkumar P. COVID-19 testing: The threat of false-negative results. Mayo Clin Proc. 2020;95(6):1127-9. doi: 10.1016/j.mayocp.2020.04.004. [PubMed: 32378102]. [PubMed Central: PMC7151274].

17. Feng H, Liu Y, Li M, Zhong J. A case report of COVID-19 with false negative RT-PCR test: necessity of chest CT. Jpn J Radiol. 2020;38(3):409-10. doi: 10.1007/s11604-020-00697-9. [PubMed: 3266524]. [PubMed Central: PMC716155].

18. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical coronavirus disease 2019 (COVID-19) Pneumonia: Relationship to negative RT-PCR testing. Radiology. 2020;296(2):445-5. doi: 10.1148/radiol.2020200341. [PubMed: 32049601]. [PubMed Central: PMC7233363].

19. Chen D, Jiang X, Hong Y, Wen Z, Wei S, Peng G, et al. Can chest CT features distinguish patients with negative from those with positive initial RT-PCR results for coronavirus disease COVID-19? AJR Am J Roentgenol. 2021;216(1):66-70. doi: 10.2214/AJR.20.23012. [PubMed: 32389282].

Rafiei Tabatabaei S et al. Arch Pediatr Infect Dis. In Press (In Press):et07644.